Partnering
Raptor's growth strategy calls for leveraging its in-house research and development capabilities through partnerships, acquisitions and collaborations. This approach has helped us to develop a balanced portfolio of product candidates with the potential to reach a broad array of underserved patient populations.
In-licensing
Raptor is interested in acquiring or in-licensing novel product candidates for development. We are particularly interested in:
- New chemical entities in mid-to late-stage clinical development
- Currently approved drugs with potential efficacy in additional indications
- Treatments that Raptor can repurpose, reformulate or improve with its selective targeting technologies to create safer, more effective or convenient treatments for their currently approved indications
Out-licensing
Raptor intends to develop and commercialize certain of its product candidates on its own and to partner product candidates that target larger markets.
Raptor is actively seeking partnerships with pharmaceutical companies for Tezampanel and NGX 426 for the potential treatment of pain and for Convivia™ in selected Asian countries to continue clinical development of Convivia™ in Asia.
Collaborations
Raptor has collaborated with several leading research institutions and nonprofit organizations as part of its efforts to improve treatments for underserved patient populations.
Intellectual Property
Raptor owns or has exclusive licenses that protect all of its product candidates and drug targeting platforms. To date, our IP portfolio consists of 15 filed and provisional patents. Maintaining freedom to operate and the ability to grow through partnerships is a critical part of our strategy.
If you're interested in discussing either a partnership or collaboration with Raptor, please contact us at .